Alpine Immune Sciences, Inc. (ALPN) Stock Analysis

Alpine Immune Sciences, Inc. (ALPN) Healthcare & Pipeline Overview

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company specializing in protein-based immunotherapies for cancer and autoimmune diseases, leveraging its unique platform to develop novel treatments like ALPN-101, ALPN-202, and ALPN-303, positioning it within the competitive biotechnology landscape.

What Is the Investment Thesis for ALPN?

Alpine Immune Sciences presents a notable research candidate within the biotechnology sector. The company's innovative pipeline, particularly ALPN-101, ALPN-202, and ALPN-303, targets significant unmet needs in autoimmune diseases and cancer. The collaboration with AbbVie for ALPN-101 validates the potential of Alpine's platform and provides financial resources for further development. Key value drivers include successful clinical trial outcomes for its lead programs, potential regulatory approvals, and expansion of its pipeline through internal research and strategic partnerships. A potential risk lies in the inherent uncertainty of clinical development and regulatory approval processes. The company's negative profit margin of -54.7% indicates that it is not currently profitable and relies on external funding or partnership revenue. Continued progress in clinical trials and strategic collaborations are essential for realizing the company's long-term value.

Based on FMP financials and quantitative analysis

ALPN Key Highlights

Market Cap of $4.46B reflects investor confidence in Alpine's pipeline and technology.

• P/E ratio of -100.94 indicates the company is currently not profitable, typical for clinical-stage biopharmaceutical companies.
• Gross Margin of -37.4% reflects high R&D expenses associated with drug development.
• Beta of 0.97 suggests the stock's volatility is similar to the overall market.
• Collaboration agreement with AbbVie for ALPN-101 provides financial support and validation of the program's potential.

Who Are ALPN's Competitors?

ALPN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ALPN's Key Strengths?

Innovative protein engineering platform.

• Promising pipeline of immunotherapies.
• Strategic collaborations with major pharmaceutical companies.
• Experienced management team.

What Are ALPN's Weaknesses?

Clinical-stage company with no currently approved products.

• High R&D expenses and negative profitability.
• Reliance on external funding and partnerships.
• Pipeline concentration on a few key programs.

What Could Drive ALPN Stock Higher?

Clinical trial data releases for ALPN-101 in autoimmune diseases.

• Clinical trial data releases for ALPN-202 in cancer immunotherapy.
• Enrollment and progression of patients in ongoing clinical trials.
• Potential for new strategic partnerships and collaborations.

What Are the Key Risks for ALPN?

Negative return on equity (-12.7%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or regulatory setbacks.
• Competition from other biotechnology and pharmaceutical companies.
• Intellectual property challenges.
• High R&D expenses and reliance on external funding.

What Are the Growth Opportunities for ALPN?

• Expansion of ALPN-101 into new autoimmune indications: ALPN-101, currently in development for autoimmune and inflammatory diseases, has the potential to be expanded into additional indications such as lupus, rheumatoid arthritis, and inflammatory bowel disease. The market for autoimmune disease therapies is estimated to reach $150 billion by 2028, offering a substantial growth opportunity for Alpine. Successful clinical trials and regulatory approvals in these new indications could significantly increase the value of ALPN-101.
• Advancement of ALPN-202 in cancer immunotherapy: ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, represents a novel approach to cancer immunotherapy. The market for cancer immunotherapies is projected to reach $75 billion by 2027. Alpine can explore ALPN-202 in combination with other cancer therapies, such as checkpoint inhibitors and chemotherapy, to enhance its efficacy and broaden its applicability across different cancer types.
• Development of ALPN-303 for B cell-mediated diseases: ALPN-303, a dual B cell cytokine antagonist, targets B cell-mediated inflammatory and autoimmune diseases. The market for B cell therapies is growing rapidly, driven by the increasing prevalence of autoimmune diseases and the development of more targeted therapies. Alpine can leverage its expertise in protein engineering to develop ALPN-303 as a differentiated therapy with improved efficacy and safety profiles.
• Strategic partnerships and collaborations: Alpine can pursue additional strategic partnerships and collaborations with pharmaceutical companies and academic institutions to accelerate the development and commercialization of its pipeline. These partnerships can provide access to additional funding, expertise, and resources, as well as expand Alpine's reach into new markets and therapeutic areas. The collaboration with AbbVie for ALPN-101 serves as a successful example of this strategy.
• Expansion into new therapeutic areas: Alpine can leverage its protein engineering platform to expand into new therapeutic areas beyond cancer and autoimmune diseases. This could include developing immunotherapies for infectious diseases, metabolic disorders, and other diseases with significant unmet needs. By diversifying its pipeline, Alpine can reduce its reliance on any single therapeutic area and create new growth opportunities.

What Are ALPN's Competitive Advantages?

• Proprietary protein engineering platform for developing novel immunotherapies.
• Strong intellectual property protection for its drug candidates.
• Strategic collaborations with leading pharmaceutical companies.
• Experienced management team with expertise in drug development and commercialization.

What Does ALPN Do?

Alpine Immune Sciences, Inc., founded in 2007 and headquartered in Seattle, Washington, is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative protein-based immunotherapies. The company's primary focus is on addressing significant unmet needs in cancer, autoimmune/inflammatory disorders, and other diseases. Alpine's scientific approach centers around modulating the immune system to achieve therapeutic benefits. Their product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist designed for the treatment of autoimmune and inflammatory diseases. ALPN-202 is a conditional CD28 costimulator and dual checkpoint inhibitor being developed for cancer therapy. ALPN-303, a dual B cell cytokine antagonist, targets B cell-mediated inflammatory and autoimmune diseases. These programs represent Alpine's commitment to developing differentiated therapies with the potential to improve patient outcomes. Alpine has established strategic collaborations to advance its pipeline, including a partnership with AbbVie Ireland Unlimited Company for the development of ALPN-101 and a collaboration with Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. The company's research and development efforts are geared towards creating novel immunotherapies that can offer improved efficacy and safety profiles compared to existing treatments.

What Products and Services Does ALPN Offer?

• Develop protein-based immunotherapies.
• Target cancer, autoimmune/inflammatory disorders, and other diseases.
• Create inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonists.
• Develop conditional CD28 costimulators and dual checkpoint inhibitors.
• Engineer dual B cell cytokine antagonists.
• Collaborate with other companies to develop next-generation SPEAR T cell products.

How Does ALPN Make Money?

• Develop novel immunotherapies through internal research and development.
• Out-license or co-develop its drug candidates with pharmaceutical partners.
• Generate revenue through upfront payments, milestone payments, and royalties from partnered programs.

What Industry Does ALPN Operate In?

Alpine Immune Sciences operates within the competitive biotechnology industry, which is characterized by rapid innovation, high R&D costs, and stringent regulatory requirements. The market for immunotherapies is experiencing significant growth, driven by advances in understanding the immune system and the increasing prevalence of cancer and autoimmune diseases. Key trends include the development of personalized therapies, the use of combination therapies, and the exploration of new immune targets. Alpine competes with other biotechnology companies developing immunotherapies, as well as established pharmaceutical companies with existing products in these therapeutic areas. The company's success depends on its ability to develop differentiated therapies with improved efficacy and safety profiles.

Who Are ALPN's Key Customers?

• Pharmaceutical companies seeking to expand their immunotherapy portfolios.
• Patients suffering from cancer and autoimmune/inflammatory disorders.
• Healthcare providers who prescribe and administer immunotherapies.

Wall Street analysts project Alpine Immune Sciences, Inc. revenue of about $9.0M for fiscal 2026, with EPS near $-2.25. The estimate reflects 7 contributing analysts.

ALPN Valuation & Market Position

With a $4.46B market cap, Alpine Immune Sciences, Inc. sits in the mid-cap segment of the market.

Return on equity for Alpine Immune Sciences, Inc. stands at -12.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -8.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.86 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.0%, the inverse of the P/E and a quick read on earnings relative to price.

Alpine Immune Sciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 64.95 places it in the safe zone, indicating low near-term bankruptcy risk.

Company Profile

Alpine Immune Sciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO Mitchell H. Gold. ALPN has traded publicly since 2015.

ALPN Financials

ALPN Latest News

No recent news available for ALPN.

What Investors Ask About Alpine Immune Sciences, Inc. (ALPN) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources